Research output per year
Research output per year
Personal profile
Research Biography
Kathie obtained her PhD from Flinders University in 1984 and a Graduate Certificate in Tertiary Education in 1997. In 2007 she was awarded an Australian Carrick Citation for outstanding contribution to student learning and in 2010 the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Teaching Excellence Award. Kathie served as ASCEPT President (2008-2009) and was awarded Life Membership of ASCEPT in 2015. She was Chairperson of the Flinders University Scholarships Committee 2005 – 2009 and Professor in Clinical Pharmacology 2008-2014. Currently she is a Professor Emeritus in the College of Medicine and Public Health.
Her main research interests were the metabolism of carboxylic acids, renal drug metabolism and the interplay between renal drug and endobiotic metabolism. She has published 71 research papers, 8 book chapters and is an author of the highly successful text Pharmacology for Health Professionals (Elsevier). She was a member of the editorial board of Drug Metabolism Reviews (2012-2018) and is currently a member of the British Journal of Clinical Pharmacology International Editorial Board (2012-2020).
Fingerprint
Dive into the research topics where Kathie Knights is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
-
Enzymology of Amino Acid Conjugation Reactions
Knights, K., 2018, Comprehensive Toxicology. McQueen (editor in chief), C. A. & Guengerich (volume editor), F. P. (eds.). 3 ed. Amsterdam, Netherlands: Elsevier, Vol. 10. p. 517-540 24 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
-
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
Miners, J., Chau, N., Rowland, A., Burns, K., McKinnon, R., Mackenzie, P., Tucker, G., Knights, K. & Kichenadasse, G., 1 Apr 2017, In: Biochemical Pharmacology. 129, p. 85-95 11 p.Research output: Contribution to journal › Article › peer-review
86 Citations (Scopus) -
The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance
Miners, J. O., Yang, X., Knights, K. M. & Zhang, L., Sept 2017, In: Pharmacology and Therapeutics. 102, 3, p. 436-449 14 p.Research output: Contribution to journal › Article › peer-review
81 Citations (Scopus) -
In Vitro Drug Metabolism Using Liver Microsomes
Knights, K., Stresser, D., Miners, J. & Crespi, C., 1 Sept 2016, Current Protocols in Pharmacology. John Wiley & Sons, Inc, Vol. 2016. p. 7.8.1-7.8.24 24 p. (Current Protocols in Pharmacology).Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review
67 Citations (Scopus) -
Scaling factors for the in vitro–in vivo extrapolation (IV–IVE) of renal drug and xenobiotic glucuronidation clearance
Knights, K., Spencer, S., Fallon, J., Chau, N., Smith, P. & Miners, J., 1 Jun 2016, In: British Journal of Clinical Pharmacology. 81, 6, p. 1153-1164 12 p.Research output: Contribution to journal › Article › peer-review
Open Access43 Citations (Scopus)
Activities
- 6 Oral presentation
-
Kinetic characterisation of S-naproxen glucuronidation by human kidney cortical microsomes and recombinant UGT 1A9 and UGT2B7
Knights, K. (Speaker), Gaganis, V. (Speaker), Burns, K. (Speaker), Elliot, D. (Speaker) & Miners, J. (Speaker)
1 Jan 2004Activity: Talk or presentation types › Oral presentation
-
NSAID-arachidonic acid interactions are intimately linked to the nephrotoxic potential of NAIDs during renal ischaemia
Gaganis, V. (Speaker), Miners, J. (Speaker) & Knights, K. (Speaker)
30 Nov 2003Activity: Talk or presentation types › Oral presentation
-
Unsaturated fatty acids: potent inhibitors of renal UDP-glucuronosyltransferases (UGT)
Gaganis, V. (Speaker), Sallustio, B. (Speaker), Miners, J. (Speaker) & Knights, K. (Speaker)
19 Aug 2003Activity: Talk or presentation types › Oral presentation
-
Fatty acids are potent inhibitors of 4-methylumbelliferone glucuronidation by human renal and recombinant UDP-glucuronosyltransferases
Gaganis, V. (Speaker), Miners, J. (Speaker), Knights, K. (Speaker) & Sallustio, B. (Speaker)
7 Jul 2002Activity: Talk or presentation types › Oral presentation
-
The effect of fatty acids on the glucuronidation of 4-methyl-um-belliferone (4-MU) by human kidney cortical microsomes
Knights, K. (Speaker), Gaganis, V. (Speaker), Miners, J. (Speaker) & Sallustio, B. (Speaker)
7 Oct 2001 → 11 Oct 2001Activity: Talk or presentation types › Oral presentation